L-Glutamine in Sickle Cell Disease: The Real-World Impact to Date
L-glutamine was approved in 2017 to treat acute complications in patients with sickle cell disease, but uptake of and adherence to it have been limited.
L-glutamine was approved in 2017 to treat acute complications in patients with sickle cell disease, but uptake of and adherence to it have been limited.
Given the rarity of CAD and lack of comparative trials, treatment plans are primarily based on findings from nonrandomized trials and clinical experience.
Researchers worked to better understand and manage patients with mild or moderate hemophilia, who can be an underrepresented and underserved population.